TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28575278

Group type: EXPERIMENTAL
Intervention: 0.5 million IU (MIU) of nebulized colistin methanesulfonate (CMS) administered every 8 hours as 30-minute nebulizations
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5 million IU (MIU) of nebulized colistin methanesulfonate (CMS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2 million IU (MIU) of nebulized colistin methanesulfonate (CMS)
Number of subjects: 12
Study: 28575299

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment during childhood
Number of subjects: 9504
Study: 28575323

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir (800/100 mg) once-daily regimen
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat (800/150 mg) once-daily regimen
Number of subjects: 7
Study: 28575467

Group type: EXPERIMENTAL
Intervention: Doxepin 6 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 28575476

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory Functioning Questionnaire (MFQ) measures
Number of subjects: 0
Study: 28575523

Group type: EXPERIMENTAL
Intervention: Fidaxomicin (16 mg/kg per day, up to 200 mg, twice daily for 10 days)
Number of subjects: 40
Study: 28575536

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 85
Study: 28576134

Group type: EXPERIMENTAL
Intervention: Higher weight gain from 6 to 9 months, 9 to 12 months, and 12 to 15 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher weight gain from 12 to 15 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight gain in any period
Number of subjects: 0
Study: 28576398

Group type: EXPERIMENTAL
Intervention: COPD symptoms frequency and 12-month evolution
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Healthcare resources utilization
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Exploratory analysis
Number of subjects: 600
Study: 28576754

Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment starting at approximately 20 mg/kg/day for 6 months, escalating to maximum tolerated dose (MTD) thereafter.
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) screening for stroke risk.
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximum tolerated dose (MTD).
Number of subjects: 122
Study: 28577353

Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg once daily plus Peginterferon α-2a/Ribavirin for 12 weeks followed by Peginterferon α-2a/Ribavirin for 12 or 36 weeks (response-guided therapy) or 36 weeks fixed (non-responders).
Number of subjects: 141
Study: 28577957

Group type: EXPERIMENTAL
Intervention: Osimertinib (AZD9291) treatment
Number of subjects: 0
Study: 28578302

Group type: EXPERIMENTAL
Intervention: Antibiotics (administered per standard of care for 5 days)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Omeprazole (administered over 14 days)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Bacteroidetes/Ascomycota ratio
Number of subjects: 143

Group type: COMPARATOR
Intervention: Cirrhotics (general population)
Number of subjects: 143
Study: 28578535

Group type: EXPERIMENTAL
Intervention: Increased daily water intake over 6 weeks
Number of subjects: 82
Study: 28578624

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization in group 1 (younger than 80 years)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization in group 2 (80 years and older)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Comparison of freedom from MALE between groups
Number of subjects: 642

Group type: COMPARATOR
Intervention: Comparison of limb salvage between groups
Number of subjects: 642
Study: 28578664

Group type: EXPERIMENTAL
Intervention: CATT (5) genotype
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: (5/5) genotype
Number of subjects: 256

Group type: COMPARATOR
Intervention: Normal-coronary subjects
Number of subjects: 256

Group type: COMPARATOR
Intervention: CAD class
Number of subjects: 256
Study: 28578691

Group type: EXPERIMENTAL
Intervention: Mild-intensity aerobic exercise
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 28578705

Group type: EXPERIMENTAL
Intervention: 1-min sit-to-stand (1-min STS) test
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Handgrip strength test
Number of subjects: 409
Study: 28578708

Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 15
Study: 28578782

Group type: EXPERIMENTAL
Intervention: Anthropometric measurements (body mass index, waist circumference, waist-to-hip ratio, waist-to-height ratio)
Number of subjects: 6268
Study: 28579503

Group type: EXPERIMENTAL
Intervention: Good School Toolkit intervention
Number of subjects: 591

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 591
Study: 28579536

Group type: EXPERIMENTAL
Intervention: Isocaloric fructose restriction for 9 days
Number of subjects: 41
Study: 28579823

Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) opioids (hydrocodone-acetaminophen and oxycodone-acetaminophen)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) opioids
Number of subjects: 354
Study: 28580433

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccination
Number of subjects: 0
Study: 28580456

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI; 6 sessions of MI + 8 weeks of NRT)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Standard Care (Brief advice to quit + 8 weeks of NRT)
Number of subjects: 430
Study: 28580793

Group type: EXPERIMENTAL
Intervention: Lanreotide plus Metformin (MET)
Number of subjects: 0
Study: 28580917

Group type: EXPERIMENTAL
Intervention: Fragment antigen-binding domains (Fabs) isolated from human monoclonal antibodies targeting NHBA
Number of subjects: 0
Study: 28581304

Group type: EXPERIMENTAL
Intervention: Maternal religiosity
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms
Number of subjects: 193
Study: 28581396

Group type: EXPERIMENTAL
Intervention: F-18 fluorodeoxyglucose (FDG) PET during chemoradiation therapy (CRT)
Number of subjects: 0
Study: 28581691

Group type: EXPERIMENTAL
Intervention: Recombinant factor XIII-A (rFXIII) prophylaxis, 35 IU/kg once monthly
Number of subjects: 6
Study: 28582238

Group type: EXPERIMENTAL
Intervention: Smart insole prototype
Number of subjects: 3
Study: 28582240

Group type: EXPERIMENTAL
Intervention: Tablet-based application (EPIC Wheels) with two in-person sessions and four weeks of independent home training
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tablet-based application (EPIC Wheels) with expert trainer monitoring
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tablet-based application (EPIC Wheels) with video instruction and interactive training games
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tablet-based application (EPIC Wheels) with standardized configuration for Wi-Fi devices
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Updated EPIC Wheels software based on pilot results
Number of subjects: 2
Study: 28582256

Group type: EXPERIMENTAL
Intervention: Video-based, algorithm-driven system (arm 3)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Video version of static handout (arm 2)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Static handout of exercises (arm 1)
Number of subjects: 860

Group type: COMPARATOR
Intervention: All arms (1, 2, and 3)
Number of subjects: 860

Group type: COMPARATOR
Intervention: Overall completion rates
Number of subjects: 860
Study: 28582580

Group type: EXPERIMENTAL
Intervention: SAPIEN 3
Number of subjects: 301

Group type: COMPARATOR
Intervention: SAPIEN XT
Number of subjects: 301
Study: 28583131

Group type: EXPERIMENTAL
Intervention: Store features with health promoting characteristics (e.g., fruit/vegetable shelf space, Healthy Food Supply Score)
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Offering ≥14 varieties of fruit/vegetables
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Produce visible from the store entrance
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Whole grain availability measures
Number of subjects: 594
Study: 28583262

Group type: EXPERIMENTAL
Intervention: Modified Spanish criteria
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: ATS Roundtable criteria
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: PLATINO criteria
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: GINA/GOLD criteria
Number of subjects: 301
Study: 28583305

Group type: EXPERIMENTAL
Intervention: DTaP5-IPV-HB-Hib vaccine administered at 2 and 6 months of age, DTaP5-IPV-Hib at 4 months, MCC vaccine at 2 and 4 months, and routine rotavirus and pneumococcal vaccination.
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Mixed schedule including DTaP5-IPV-HB-Hib and MCC vaccine.
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Mixed schedule with hexavalent vaccine and MCC vaccine.
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine co-administered with MCC vaccine.
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Study vaccine doses.
Number of subjects: 385
Study: 28583617

Group type: EXPERIMENTAL
Intervention: Implantable IV infusion system for treprostinil
Number of subjects: 64
Study: 28583826

Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR)
Number of subjects: 2106
Study: 28584140

Group type: EXPERIMENTAL
Intervention: CRS3123 (Methionyl-tRNA Synthetase Inhibitor)
Number of subjects: 0
Study: 28584142

Group type: EXPERIMENTAL
Intervention: Micafungin treatment
Number of subjects: 10
Study: 28584252

Group type: EXPERIMENTAL
Intervention: ATRA plus anthracycline-based regimens (LPA2005 trial)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Non-age-adapted schedules (LPA96&LPA99 trials)
Number of subjects: 268
Study: 28586789

Group type: EXPERIMENTAL
Intervention: Positive SWOG treatment trials
Number of subjects: 12361
Study: 28586923

Group type: EXPERIMENTAL
Intervention: Next-generation metagenomic sequencing (NGMS)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Quantitative PCR assay for HHpgV-1
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: NGMS
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: HHpgV-1 viremia
Number of subjects: 156
Study: 28587613

Group type: EXPERIMENTAL
Intervention: DPP4a
Number of subjects: 625
Study: 28587667

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 652

Group type: COMPARATOR
Intervention: Basal insulin peglispro (BIL) and insulin glargine
Number of subjects: 652
Study: 28588018

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical HSCT after αβ T-cell and B-cell depletion
Number of subjects: 80
Study: 28588020

Group type: EXPERIMENTAL
Intervention: Enasidenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28588383

Group type: EXPERIMENTAL
Intervention: Severe Respiratory Insufficiency (SRI) Questionnaire
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Maugeri Respiratory Failure (MRF) Questionnaire
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 56
Study: 28588421

Group type: EXPERIMENTAL
Intervention: Novel product containing glycolic acid, sodium bicarbonate, glycerin, and other buffering agents, applied once before irrigation with warm water
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Novel product with irrigation instructions followed
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Novel product application
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Application satisfaction assessment
Number of subjects: 30
Study: 28588426

Group type: EXPERIMENTAL
Intervention: Ramadan fasting (RF) with clopidogrel at a maintenance dose of 75 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Clopidogrel at a maintenance dose of 75 mg without Ramadan fasting
Number of subjects: 98
Study: 28588946

Group type: EXPERIMENTAL
Intervention: Free RDT
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy
Number of subjects: 444

Group type: COMPARATOR
Intervention: No testing (control)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy with free RDT
Number of subjects: 444
Study: 28588962

Group type: EXPERIMENTAL
Intervention: Community-based early childhood intervention package
Number of subjects: 526

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 526
Study: 28588982

Group type: EXPERIMENTAL
Intervention: RUTF-L
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: RUTF-C
Number of subjects: 906

Group type: COMPARATOR
Intervention: A-HPF
Number of subjects: 906
Study: 28588992

Group type: EXPERIMENTAL
Intervention: mRDTs (malaria rapid diagnostic tests) introduced in drug shops
Number of subjects: 0
Study: 28589002

Group type: EXPERIMENTAL
Intervention: Pigs for Peace (PFP) intervention
Number of subjects: 833
Study: 28588977

Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery in low-HDI countries
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery in middle-HDI countries
Number of subjects: 1409

Group type: COMPARATOR
Intervention: High-HDI countries
Number of subjects: 1409
Study: 28589492

Group type: EXPERIMENTAL
Intervention: LY2874455 at 16 mg BID (RP2D)
Number of subjects: 36
Study: 28590109

Group type: EXPERIMENTAL
Intervention: Gluten-free dish availability in food locals
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Adequate elaboration of gluten-free dishes
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Appropriate food storage
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Adequate distribution of gluten-free dishes
Number of subjects: 112
Study: 28590796

Group type: EXPERIMENTAL
Intervention: MR imaging-guided high-intensity focused ultrasound (HIFU)
Number of subjects: 45
Study: 28591336

Group type: EXPERIMENTAL
Intervention: Multivisceral en bloc resection
Number of subjects: 105
Study: 28591824

Group type: EXPERIMENTAL
Intervention: 100 kV with standard iterative reconstruction (IR)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 80 kV with standard IR
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 80 kV with strong IR
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 100 kV protocols
Number of subjects: 14

Group type: COMPARATOR
Intervention: 120 kV with standard IR (reference)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 100 kV with standard IR
Number of subjects: 14
Study: 28592230

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin for CS-GNB patients
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Directed prophylaxis for CR-GNB patients
Number of subjects: 510
Study: 28592237

Group type: EXPERIMENTAL
Intervention: PartoMa guidelines
Number of subjects: 84
Study: 28592289

Group type: EXPERIMENTAL
Intervention: Excessive weight-for-length at enrolment
Number of subjects: 642

Group type: COMPARATOR
Intervention: Weight-for-length at enrolment
Number of subjects: 642

Group type: COMPARATOR
Intervention: AD at two years
Number of subjects: 642

Group type: COMPARATOR
Intervention: AD at any time
Number of subjects: 642
Study: 28592297

Group type: EXPERIMENTAL
Intervention: ANCA-negative at the time of switching to maintenance therapy
Number of subjects: 252

Group type: COMPARATOR
Intervention: ANCA-positive at the time of switching to maintenance therapy
Number of subjects: 252
Study: 28592313

Group type: EXPERIMENTAL
Intervention: Community-initiated Kangaroo Mother Care (cKMC)
Number of subjects: 0
Study: 28592319

Group type: EXPERIMENTAL
Intervention: Daily 360 μg of menaquinone-7 for 4 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline dp-ucMGP levels
Number of subjects: 50
Study: 28592387

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (oral dabrafenib 150 mg twice per day and oral trametinib 2 mg once per day)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 125
Study: 28592434

Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment for 2 years, starting at 5 mg once daily, uptitrated to 10 mg (age 6-<10 years) or 20 mg (age 10-<18 years).
Number of subjects: 197

Group type: COMPARATOR
Intervention: Untreated unaffected siblings
Number of subjects: 197
Study: 28592512

Group type: EXPERIMENTAL
Intervention: Higher maternal protein intake during pregnancy
Number of subjects: 0
Study: 28592516

Group type: EXPERIMENTAL
Intervention: Maternal night-fasting interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28592572

Group type: EXPERIMENTAL
Intervention: Iron intervention (micronutrient powders containing vitamins and minerals with iron)
Number of subjects: 1943

Group type: COMPARATOR
Intervention: No-iron group (control)
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Both groups (combined analysis)
Number of subjects: 1943
Study: 28592602

Group type: EXPERIMENTAL
Intervention: Cholecystokinin responsiveness
Number of subjects: 0
Study: 28592604

Group type: EXPERIMENTAL
Intervention: Biomarkers of environmental enteropathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28592612

Group type: EXPERIMENTAL
Intervention: Fried potato consumption
Number of subjects: 0
Study: 28592616

Group type: EXPERIMENTAL
Intervention: Panitumumab (6 mg/kg, administered intravenously every 2 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 33
Study: 28592615

Group type: EXPERIMENTAL
Intervention: Cobimetinib and duligotuzumab combination
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Duligotuzumab
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cobimetinib
Number of subjects: 23
Study: 28592624

Group type: EXPERIMENTAL
Intervention: Pemetrexed 150 mg/m2 via 8-hour intravenous infusion followed by gemcitabine
Number of subjects: 14
Study: 28593306

Group type: EXPERIMENTAL
Intervention: Small nodal tumor infiltrates (SNTI)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Bone marrow micrometastases (BMM)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combined detection of BMM and SNTI
Number of subjects: 122
Study: 28593789

Group type: EXPERIMENTAL
Intervention: Cancer group
Number of subjects: 926

Group type: COMPARATOR
Intervention: Non-cancer group
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors
Number of subjects: 926
Study: 28594116

Group type: EXPERIMENTAL
Intervention: IgPro10
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28594193

Group type: EXPERIMENTAL
Intervention: Self-reported TBI
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: History of multiple TBIs
Number of subjects: 857
Study: 28594442

Group type: COMPARATOR
Intervention: BMI <20.32 kg/m² (lowest quartile)
Number of subjects: 29446

Group type: EXPERIMENTAL
Intervention: BMI quartiles (higher than 20.32 kg/m²)
Number of subjects: 29446
Study: 28594711

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (16 weeks, repeated yearly for 3 years)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (second program, month 12-16)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (last program, month 24-28)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sedentary lifestyle (control group)
Number of subjects: 49
Study: 28594762

Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention using a tablet computer-based decision aid for opioid prescribing after cesarean delivery.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard prescription of 40 tablets of 5 mg oxycodone.
Number of subjects: 51
Study: 28595189

Group type: EXPERIMENTAL
Intervention: Oral BCAA (30.7 ± 1.1 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: IV BCAA (30.7 ± 1.1 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both BCAA tests
Number of subjects: 18
Study: 28595298

Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg once daily
Number of subjects: 16
Study: 28595339

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT-D)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT-D) responders
Number of subjects: 133

Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 133
Study: 28595616

Group type: EXPERIMENTAL
Intervention: Oral ridaforolimus 30 mg daily for 5 consecutive days per week combined with intravenous paclitaxel 175 mg/m2
Number of subjects: 24
Study: 28595644

Group type: EXPERIMENTAL
Intervention: 19-gene qRT-PCR panel
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Changes in gene expression
Number of subjects: 21
Study: 28596770

Group type: EXPERIMENTAL
Intervention: 6-month booster regimen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 12-month booster regimen
Number of subjects: 12
Study: 28596794

Group type: EXPERIMENTAL
Intervention: Herbal therapy (5 shenwu capsules/administration, 3 times/day)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Donepezil (placebo identical to donepezil tablets)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Herbal therapy
Number of subjects: 324
Study: 28596863

Group type: EXPERIMENTAL
Intervention: Parents Make the Difference (PMD) intervention
Number of subjects: 270
Study: 28596983

Group type: EXPERIMENTAL
Intervention: 22G Procore needle using standard suction technique (SST)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 22G Procore needle using capillary suction technique (CST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 25G needle (control)
Number of subjects: 60
Study: 28597337

Group type: EXPERIMENTAL
Intervention: Brain reward responses to food stimuli
Number of subjects: 32